Daré Bioscience (NASDAQ:DARE – Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.02, Zacks reports.
Daré Bioscience Price Performance
Shares of NASDAQ DARE traded up $0.01 during mid-day trading on Monday, hitting $2.89. The company had a trading volume of 20,264 shares, compared to its average volume of 45,555. Daré Bioscience has a 1-year low of $2.67 and a 1-year high of $7.56. The company has a market capitalization of $25.14 million, a PE ratio of -4.89 and a beta of 1.38. The business’s 50-day simple moving average is $3.07 and its 200 day simple moving average is $3.29.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a research report on Tuesday, December 17th.
Daré Bioscience Company Profile
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Articles
- Five stocks we like better than Daré Bioscience
- 5 Top Rated Dividend Stocks to Consider
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Using the MarketBeat Dividend Yield Calculator
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Short Selling – The Pros and Cons
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
